CYRX - Cryoport Tanks On Chilling Results And Bad Decisions

2024-03-14 11:56:14 ET

Summary

• Cryoport, Inc.'s financial results for Q4 2023 fell short of expectations, with revenue declining and a significant net loss.
• Despite the potential for growth in the cell and gene therapy market, Cryoport's revenue growth is expected to be modest.
• Management's decision to buy back shares instead of focusing on growth raises concerns about the company's future prospects.
• The company's bottom line also makes it a difficult opportunity to justify.

The search for interesting companies sometimes leads me to some really attractive prospects. Other times, the opposite is true. One company that I have been consistently bearish about but that I find to be fascinating from an operational perspective is none other than Cryoport, Inc. ( CYRX )....

For further details see: